Paulina Selaru
-
- Lung Cancer Treatments and Mutations 22
- Lung Cancer Diagnosis and Treatment 4
- Gastric Cancer Management and Outcomes 3
- Oncology top 2%
- Lung Cancer Research Studies 11
- Colorectal Cancer Treatments and Studies 9
- Peptidase Inhibition and Analysis 3
- Pancreatic and Hepatic Oncology Research 2
- Cancer Research top 10%
- Cancer Genomics and Diagnostics 3
- Molecular Biology top 10%
- Co-authors
- Keith D. WilnerGregory J. RielyLucio CrinòBenjamin SolomonDaniel B. CostaRichard C. ChaoL. TyeRamaswamy Govindan
- Partner nations
- United StatesItalyChina
In The Last Decade
Paulina Selaru
26 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 69
- Pulmonary and Respiratory Medicine 1.8k
- Oncology 1.4k
- Cancer Research 285
- Pathology and Forensic Medicine 231
- Molecular Biology 819
Countries citing papers authored by Paulina Selaru
This map shows the geographic impact of Paulina Selaru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paulina Selaru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paulina Selaru more than expected).
Fields of papers citing papers by Paulina Selaru
This network shows the impact of papers produced by Paulina Selaru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paulina Selaru. The network helps show where Paulina Selaru may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Paulina Selaru, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 137 | |
| 2 | 2018 | 74 | |
| 3 | 2017 | 0 | |
| 4 | Intracranial efficacy of first-line crizotinib vs. chemotherapy in ALK-positive NSCLC | 2015 | 1 |
| 5 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasesbreakdown → | 2015 | 468 |
| 6 | 2014 | 170 | |
| 7 | 2013 | 47 | |
| 8 | 2012 | 36 | |
| 9 | 2011 | 14 | |
| 10 | 2011 | 28 | |
| 11 | 2010 | 53 | |
| 12 | 2010 | 188 | |
| 13 | 2009 | 4 | |
| 14 | 2009 | 110 | |
| 15 | 2009 | 1 | |
| 16 | Effect of food on the pharmacokinetics of Axitinib (AG-013736) in healthy volunteers | 2008 | 3 |
| 17 | 2008 | 28 | |
| 18 | Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer | 2007 | 13 |
| 19 | 2003 | 49 | |
| 20 | 2001 | 266 |
About Paulina Selaru
Paulina Selaru is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Ophthalmology, having authored 27 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (11 papers), Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Diagnosis and Treatment (4 papers), Peptidase Inhibition and Analysis (3 papers), Cancer Genomics and Diagnostics (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.8k citations), Oncology (1.4k citations) and Cancer Research (285 citations). Paulina Selaru has collaborated with scholars based in United States, Italy and China. Frequent co-authors include Keith D. Wilner, Gregory J. Riely, Lucio Crinò, Benjamin Solomon, Daniel B. Costa, Richard C. Chao, L. Tye, Ramaswamy Govindan, Giorgio V. Scagliotti and Alice T. Shaw. Their work appears in journals such as Circulation, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.